ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. Dokkyo Journal of Medical Sciences
  2. 46(3) 2019

Phase I Trial of Pemetrexed in Combination with Carboplatin Followed by Pemetrexed Maintenance Therapy in Elderly Patients with Advanced Non-small Cell Lung Cancer

https://dmu.repo.nii.ac.jp/records/2243
https://dmu.repo.nii.ac.jp/records/2243
ec088b25-afaa-4862-9bf8-7fd58bc6f8df
名前 / ファイル ライセンス アクション
DJMS-46-3-3.pdf DJMS-46-3-Soda-本文 (287.9 kB)
Item type 学術雑誌論文 / Journal Article(1)
タイトル
タイトル Phase I Trial of Pemetrexed in Combination with Carboplatin Followed by Pemetrexed Maintenance Therapy in Elderly Patients with Advanced Non-small Cell Lung Cancer
言語
言語 eng
キーワード
主題Scheme Other
主題 elderly
キーワード
主題Scheme Other
主題 advanced non-small cell lung cancer
キーワード
主題Scheme Other
主題 carboplatin
キーワード
主題Scheme Other
主題 pemetrexed
キーワード
主題Scheme Other
主題 maintenance therapy
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
著者 Soda, Sayo

× Soda, Sayo

en Soda, Sayo

Search repository
Arai, Ryo

× Arai, Ryo

en Arai, Ryo

Search repository
Ito, Hiroshi

× Ito, Hiroshi

en Ito, Hiroshi

Search repository
Uchida, Nobuhiko

× Uchida, Nobuhiko

en Uchida, Nobuhiko

Search repository
Shimizu, Yuka

× Shimizu, Yuka

en Shimizu, Yuka

Search repository
Koike, Ryosuke

× Koike, Ryosuke

en Koike, Ryosuke

Search repository
Nakamura, Yusuke

× Nakamura, Yusuke

en Nakamura, Yusuke

Search repository
Masawa, Meitetsu

× Masawa, Meitetsu

en Masawa, Meitetsu

Search repository
Okutomi, Tomoko

× Okutomi, Tomoko

en Okutomi, Tomoko

Search repository
Okutomi, Hiroaki

× Okutomi, Hiroaki

en Okutomi, Hiroaki

Search repository
Morita, Hiroko

× Morita, Hiroko

en Morita, Hiroko

Search repository
Yokoyama, Tatsuya

× Yokoyama, Tatsuya

en Yokoyama, Tatsuya

Search repository
Watanabe, Taiji

× Watanabe, Taiji

en Watanabe, Taiji

Search repository
Ikeda, Naoya

× Ikeda, Naoya

en Ikeda, Naoya

Search repository
Shiobara, Taichi

× Shiobara, Taichi

en Shiobara, Taichi

Search repository
Hayashi, Yumeko

× Hayashi, Yumeko

en Hayashi, Yumeko

Search repository
Funakoshi, Tomoe

× Funakoshi, Tomoe

en Funakoshi, Tomoe

Search repository
Miyoshi, Masaaki

× Miyoshi, Masaaki

en Miyoshi, Masaaki

Search repository
Chibana, Kazuyuki

× Chibana, Kazuyuki

en Chibana, Kazuyuki

Search repository
Takemasa, Akihiro

× Takemasa, Akihiro

en Takemasa, Akihiro

Search repository
Shimizu, Yasuo

× Shimizu, Yasuo

en Shimizu, Yasuo

Search repository
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
著者所属
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
書誌情報 Dokkyo Journal of Medical Sciences

巻 46, 号 3, p. 113-123, 発行日 2019-10-25
要旨
内容記述タイプ Other
内容記述 Introduction: A phase I trial was conducted to evaluate the feasibility of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy in elderly patients with advanced non-small cell lung cancer (NSCLC). The primary objective of this study was to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of pemetrexed in combination with carboplatin.
Methods:Chemotherapy-naïve elderly 13 patients (age, ≥70 years) with stage IIIB/IV non-squamous NSCLC were enrolled and received pemetrexed 500 mg/m2 and carboplatin at an area under the curve (AUC)dose of 5 mg/ml/min(level 1)or 6 mg/ml/min (level 2). Pemetrexed with carboplatin was administered on day 1 of the 21-day cycle. The treatment schedule consisted of four cycles of pemetrexed with carboplatin. Patients who did not have progressive disease after completion of four cycles subsequently received pemetrexed maintenance therapy (500 mg/m2 every three weeks) until disease progression or unacceptable toxicity was noted.
Results:Three patients were enrolled in level 1, in which no dose-limiting toxicity(DLT)was observed. The carboplatin dose was escalated to AUC 6. Two of 3 patients treated in level 2 had grade 4 thrombocytopenia of DLT. MTD was determined as level 2. Consequently, pemetrexed 500 mg/m2 with carboplatin AUC 5 was recommended as the dose for elderly patients with advanced non-squamous NSCLC. An additional 7 patients who received RD showed no DLT. Nine of 13 patients received 4 cycles of combination therapy, and 5 patients were continuously treated with pemetrexed maintenance therapy. Six patients achieved a partial response, and another 6 showed stable disease. The response rate and disease control rate were 46.2% and 92.3%, respectively. The median progression-free survival for the enrolled patients was 134 days (95% CI, 95 to 231 days), and the median overall survival was 346 days (95% CI, 151 to 549 days).
Conclusions:The combination therapy of pemetrexed 500 mg/m2 with carboplatin AUC 5 followed by pemetrexed maintenance therapy showed no severe adverse events and was feasible and well-tolerated for elderly patients with advanced non-squamous NSCLC.
記事種別
Original
出版者
出版者 獨協医学会
ISSN
収録物識別子タイプ ISSN
収録物識別子 03855023
書誌レコードID
収録物識別子タイプ NCID
収録物識別子 AA00629581
戻る
0
views
See details
Views

Versions

Ver.1 2023-06-20 15:31:24.050310
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3